Cantor Fitzgerald analyst Joseph Foresi raised his price target for Exponent to $82 saying the company reported strong revenue growth in Q3. The analyst expects revenues to return to high single-digit growth in 2017 and 2018 and keeps an Overweight rating on the shares.

Consensus $487.34M. EBITDA to be 26.25% to 27.0% of revenues before reimbursements.

Reports Q1 revenue $144.9M, consensus $125.98M. "Exponent delivered better than expected results in the first quarter, as we grew revenues before reimbursements 7% and expanded earnings per share year over year. This is a testament to our highly diversified portfolio and the merits of our premium service offerings to multiple industries," commented Dr. Catherine Corrigan, President and Chief Executive Officer. "We continued to deepen our roots in reactive work, which grew in the mid-teens, driven by robust failure analysis and dispute-related work across a wide spectrum of industries. From wind farms to life saving medical devices, clients around the world increasingly rely on Exponent's unrivaled failure analysis expertise to provide critical, real-time insights on regulatory and safety related decisions. "Exponent's team of experts continues to advise clients on critical needs throughout the product lifecycle. Our proactive business, excluding consumer electronics which continues to experience cyclical impacts, increased year over year driven by strength in the transportation, utilities and chemical sectors. "The increasing global attention on safety, health, and environmental concerns coupled with the complexity and pace of innovation continues to drive greater demand for our expertise," continued Dr. Corrigan. "Exponent remains well positioned to serve our clients and deliver mission-critical insights for the present while paving the way for future innovations."